Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection

Chest

Volumn 140, Issue 4, 2011, Pages 1025-1032

  Viasus, Diego ^a   Paño Pardo, José Ramón ^b   Pachón, Jerónimo ^c   Riera, Melchor ^d   López Medrano, Francisco ^e   Payeras, Antoni ^f   Fariñas, M Carmen ^g   Moreno, Asunción ^h   Rodríguez Baño, Jesús ⁱ   Oteo, José Antonio ^j   Ortega, Lucia ^k   Torre Cisneros, Julián ^l   Segura, Ferrán ^m   Carratalà, Jordi ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL SON LLÀTZER   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j HOSPITAL SAN PEDRO   (Spain)

^k Scias Hospital Barcelona   (Spain)

^l Hospital Universitario Reina Sofia Cordoba   (Argentina)

^m HOSPITAL DE SABADELL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CORTICOSTEROID; OSELTAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CAUSE OF DEATH; CHRONIC LUNG DISEASE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMORBIDITY; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; FEVER; HEART DISEASE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; INFLUENZA VIRUS A H1N1; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MENTAL DISEASE; MIXED INFECTION; MORBID OBESITY; MORTALITY; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY FAILURE; SMOKING; TREATMENT DURATION;

EID: 80053466013     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2792     Document Type: Article

References (26)

1. Dawood FS, Jain S, Finelli L, et al; Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009;360(25):2605-2615.
2. Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/h1n1flu/recommendations.htm. Accessed October 5, 2010.
3. Morgan OW, Bramley A, Fowlkes A, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS ONE. 2010;5(3):e9694. http://www.plosone.org/article/info%3Adoi%2F10. 1371%2Fjournal.pone.0009694. Accessed August 1, 2010.
4. La Ruche G, Tarantola A, Barboza P, Vaillant L, Gueguen J, Gastellu-Etchegorry M; Epidemic Intelligence Team at InVS. The 2009 pandemic H1N1 influenza and indigenous populations of the Americas and the Pacific. Euro Surveill. 2009;14(42). pii: 19366. http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId 5 19366. Accessed December 22, 2009.
5. Centers for Disease Control and Prevention (CDC). Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives-12 states, 2009. MMWR Morb Mortal Wkly Rep. 2009;58(48):1341-1344.
6. Jain S, Kamimoto L, Bramley AM, et al; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med. 2009;361(20):1935-1944.
7. Louie JK, Acosta M, Jamieson DJ, Honein MA; California Pandemic (H1N1) Working Group. Severe 2009 H1N1 influenza in pregnant and postpartum women in California. N Engl J Med. 2010;362(1):27-35.
8. Chien YS, Su CP, Tsai HT, et al. Predictors and outcomes of respiratory failure among hospitalized pneumonia patients with 2009 H1N1 influenza in Taiwan. J Infect. 2010;60(2):168-174.
9. Viasus D, Paño-Pardo JR, Pachón J, et al. Factors associated with severe disease in hospitalised adults with pandemic (H1N1) 2009 in Spain. Clin Microbiol Infect. 2010;17(5):738-746.
10. Falagas ME, Koletsi PK, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Rello J. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(7):1330-1346.
11. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009;339:b5106. http://www.bmj.com/content/339/bmj.b5106. Accessed January 15, 2010.
12. Harper SA, Bradley JS, Englund JA, et al Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children - diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(8):1003-1032.
13. Ison MG, Gnann JW Jr, Nagy-Agren S, et al NIAID Collaborative Antiviral Study Group. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther. 2003;8(3):183-190. (Pubitemid 36960891)
14. Cui W, Zhao H, Lu X, et al. Factors associated with death in hospitalized pneumonia patients with 2009 H1N1 influenza in Shenyang, China. BMC Infect Dis. 2010;10:145. http://www.biomedcentral.com/1471-2334/10/145. Accessed June 30, 2010.
15. Uyeki T. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1). N Engl J Med. 2009;361(23):e110.
16. World Health Organization. Interim WHO guidance for the surveillance of human infection with swine influenza A(H1N1) virus, 27 April 2009. World Health Organization Web site. http://www.who.int/csr/disease/swineflu/WHO-case- definitions.pdf. Accessed June 1, 2009.
17. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
18. McGeer A, Green KA, Plevneshi A, et al Toronto Invasive Bacterial Diseases Network. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45(12):1568-1575. (Pubitemid 351411840)
19. Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther. 2007;12(4):501-508. (Pubitemid 47041148)
20. Lee N, Cockram CS, Chan PK, Hui DS, Choi KW, Sung JJ. Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes. Clin Infect Dis. 2008;46(8):1323-1324. (Pubitemid 351589924)
21. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200(4):492-500.
22. Leekha S, Zitterkopf NL, Espy MJ, Smith TF, Thompson RL, Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol. 2007;28(9):1071-1076. (Pubitemid 47345268)
23. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. BMJ. 2010;341:c4779. http://www.bmj.com/content/341/bmj.c4779. Accessed October 10, 2010.
24. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010;202(8):1154-1160.
25. Li IW, Hung IF, To KK, et al. The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest. 2010;137(4):759-768.
26. Cao B, Li XW, Mao Y, et al; National Influenza A Pandemic (H1N1) 2009 Clinical Investigation Group of China. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009;361(26):2507-2517.